-

09:53:45 AM

IFRX Stock News

IFRX - InflaRx N.V.

08/05/22 7:00 AM

Nasdaq : IFRX

InflaRx Reports Second Quarter 2022 Financial & Operating Results

Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDA Plans to submit EUA with the FDA for vilobelimab in critically ill COVID-19 patients announced Grant income of €14.4 million realized during the second quarter Cash, cash equivalents and

RHEA-AI

neutral

07/26/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement

RHEA-AI

neutral

07/06/22 7:30 AM

Nasdaq : IFRX

InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage

RHEA-AI

very positive

06/29/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design Type B meeting scheduled with FDA; dialogue ongoing with EMA for development in severe

RHEA-AI

positive

05/17/22 7:30 AM

Nasdaq : IFRX

conferences

InflaRx to Present at the H.C. Wainwright Global Investment Conference

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will give a company presentation at the upcoming H.C. Wainwright

RHEA-AI

neutral

05/12/22 7:30 AM

Nasdaq : IFRX

InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update

Quarter highlighted by progress with vilobelimab in several indications : Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underway Final data from Phase IIa open-label study in patients with pyoderma gangrenosum

RHEA-AI

neutral

03/31/22 7:30 AM

Nasdaq : IFRX

covid-19

InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients

Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (p-value=0.094), but did not show statistical significance on the pre-specified primary endpoint Pre-specified sensitivity analysis of the primary endpoint results in p-values of <0.05 in

RHEA-AI

neutral

03/24/22 7:30 AM

Nasdaq : IFRX

InflaRx Reports Full Year 2021 Financial and Operating Results

Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa Positive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual Meeting Topline data in vilobelimab Phase III

RHEA-AI

neutral

03/17/22 7:30 AM

Nasdaq : IFRX

InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today reported that the Company has received a corrected advice letter from the U.S. Food and

RHEA-AI

neutral

03/08/22 7:30 AM

Nasdaq : IFRX

InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced that final data from the Company’s Phase IIa open-label study with vilobelimab in

RHEA-AI

neutral

IFRX Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.inflarx.de
Security nameInflaRx N.V.
Issue typecs
SectorManufacturing
Sic code2834
Employees49
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressWinzerlaer Str. 2
StateThueringen
CityJena
Zip07745
CountryGermany
Phone493641508180

About InflaRx N.V.

InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.